ARID1A deficiency reprograms the tumor secretome, enhancing microenvironmental remodeling and metastatic dissemination in endometrial carcinoma - PubMed
3 hours ago
- #tumor secretome
- #ARID1A deficiency
- #metastasis
- ARID1A deficiency in endometrial carcinoma (EC) reprograms the tumor secretome, enhancing tumor microenvironment remodeling and metastasis.
- CXCL16 is identified as the predominant chemokine in ARID1A-deficient EC, promoting epithelial-to-mesenchymal transition and cell invasiveness.
- CXCL16 activates MAPK and Paxillin/FAK pathways, driving YAP/TAZ signaling and fostering pro-tumorigenic features.
- Elevated CXCL16 levels convert stromal cells into cancer-associated fibroblasts (CAFs) in preclinical models and patient samples.
- Inhibition of the CXCL16-CXCR6 axis disrupts pathogenic interactions, impairing EC cell migration and reducing metastatic burden, highlighting its therapeutic potential.